Compare Diageo plc (DEO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Twist Bioscience Corp — how do they compare? Diageo plc trades at $87.35 (market cap $47.54B), while Twist Bioscience Corp trades at $157.7 (market cap $10.32B). The key difference: Diageo plc is far larger — about 4.6× Twist Bioscience Corp's market cap, and Diageo plc pays a 2.36% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Twist Bioscience Corp for 27 Days on average.
| DEO | TWST | |
|---|---|---|
Market Cap | $47.54B | $10.32B |
Volume | 1,824,704 | 5,894,998 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $205.00 |
52-Week Low | $72.47 | $25.45 |
Typical Hold Time | 66 Days | 27 Days |
Enterprise Value | $67.96B | $10.24B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
